News

Anti-EBV trial results explained by Professor Michael Pender

About the Anti-EBV clinical trial

A treatment to target EBV has been shown to improve symptoms in some people with progressive MS in a world-first clinical trial.

The small phase I safety trial used an ‘adoptive T cell immunotherapy’ treatment. This involves taking blood from patients, extracting their immune cells, and then ‘training’ these cells in the lab to recognise and destroy EBV. The cells are then reintroduced to the patient’s body and go to work in targeting the EBV hiding in the body.

The trial was carried out by Professor Michael Pender and Professor Rajiv Khanna and MS Research Australia is proud to have contributed to the funding of this project, as well as significantly supporting Professor Pender’s EBV research over the last decade.

In this video Professor Pender explains how the trial came about, what it involved and what the results may mean for the future.

About Professor Michael Pender

Professor Michael Pender is a neurologist and researcher from The University of Queensland and Royal Brisbane and Women’s Hospital. He has spent much of his career investigating EBV in MS with a great deal of support along the way from MS Research Australia.

CEO Rohan Greenland signs the condolence book

From our CEO

Recently, I was honoured to be appointed as the Chair of the Neurological Alliance Australia. So, what does this mean for the MS community?
Des Graham enjoying getting out in nature

A better NDIS for all Australians

Associate Professor Des Graham is Chair of MS Australia and lives with multiple sclerosis. Here he describes his experiences navigating the NDIS and outlines MS Australia’s campaign, A better NDIS for people living with MS.

What us to keep you in the loop? Subscribe today!

  • Enter your details

Read More
Anti-EBV trial promising for progressive MSsex hormones in MS

Newsletter subscription

  • Enter your details

Anti-EBV trial results explained by Professor Michael Pender